Heart transplant patients may get safer virus protection
NCT ID NCT07079735
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a newer drug, letermovir, is safer and more effective than the standard valganciclovir for preventing CMV infection in heart transplant recipients. About 150 moderate- to high-risk adults will be enrolled. The main focus is on reducing side effects like low white blood cell counts while still preventing the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir and valganciclovir (antiviral drugs)
What this could lead to
If letermovir works better with fewer side effects, it could become the new standard for preventing CMV in heart transplant patients.
What could go wrong
This is a mid-stage trial with only 150 participants, so results may not apply to everyone. Both drugs have known side effects like low white blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV VIREMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University/NYP Milstein Hospital
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NYP-Weill Cornell
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact